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Towards smart self-clearing glaucoma
drainage device
Hyunsu Park1, Amir Hossein Raffiee2, Simon W. M. John3, Arezoo M. Ardekani2 and Hyowon Lee1
Abstract
For patients who are unresponsive to pharmacological treatments of glaucoma, an implantable glaucoma drainage
devices (GDD) are often used to manage the intraocular pressure. However, the microscale channel that removes
excess aqueous humor from the anterior chamber often gets obstructed due to biofouling, which necessitates
additional surgical intervention. Here we demonstrate the proof-of-concept for smart self-clearing GDD by integrating
magnetic microactuators inside the drainage tube of GDD. The magnetic microactuators can be controlled using
externally applied magnetic fields to mechanically clear biofouling-based obstruction, thereby eliminating the need for
surgical intervention. In this work, our prototype magnetic microactuators were fabricated using low-cost maskless
photolithography to expedite design iteration. The fabricated devices were evaluated for their static and dynamic
mechanical responses. Using transient numerical analysis, the fluid–structure interaction of our microactuator inside a
microtube was characterized to better understand the amount of shear force generated by the device motion. Finally,
the anti-biofouling performance of our device was evaluated using fluorescein isothiocyanate labeled bovine serum
albumin. The microactuators were effective in removing proteinaceous film deposited on device surface as well as on
the inner surface of the microchannel, which supports our hypothesis that a smart self-clearing GDD may be possible
by integrating microfabricated magnetic actuators in chronically implanted microtubes.
Introduction
Glaucoma is a group of eye diseases that causes pro-
gressive damage to optic nerve. It is commonly known as
“the silent thief of sight” due to the lack of symptoms
during the early stages1. Because of this difficulty in early
diagnosis, glaucoma remains as one of the leading causes
of blindness and visual impairments in the world2. It
currently affects around 64.3 million people in the world
and this number is expected to double by 20403,4. In the
United States, there are more than 3 million patients with
glaucoma and it disproportionally affects African Amer-
icans and Hispanics5–9. Glaucoma is a major healthcare
issue with the annual cost for treatment in the US that
exceeds $2.9 billion10.
Typically, glaucoma patients experience poor drainage
of aqueous humor (AH) through the natural outflow
pathways (i.e., trabecular meshwork and Schlemm’s
canal)11. The imbalance between the rate of production
and the outflow of AH from the eye causes an increased
intraocular pressure (IOP), which is a major risk factor
that leads to subsequent damage to optic nerve and the
loss of eyesight12,13. Unfortunately, there is no cure for
glaucoma. However, the progression of disease can sig-
nificantly be delayed using pharmaceutical and surgical
interventions that maintain the IOP in a safe range to
minimize optic nerve damage14. Glaucoma drugs are
typically designed to decrease the production of AH or to
increasing its outflow through trabecular meshwork or
uveoscleral pathway15–18. As with most pharmaceutical
interventions, however, these drugs have several unde-
sirable side effects including bitter taste, headache,
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conjunctivitis, visual blurring, eyelid inflammation, and
eye pain19–21. Surgical treatments such as trabeculectomy
and laser trabeculoplasty can also be used to increase AH
outflow but these invasive procedures often lead to ser-
ious post-operative complications such as hypotony, cat-
aract, and bleb-related infections22–25. Moreover, the
surgical ablation of trabecular meshwork often results in
coagulative necrotic tissue, which can cause difficulty in
chronic management of optimal AH outflow26.
For patients with refractory or inflammatory glaucoma
who are unresponsive to conventional pharmacological or
surgical procedures, glaucoma drainage device (GDD) are
often implanted. These devices offer several advantages
over conventional trabeculectomy including better IOP
control, ease of surgery, and minimum post-surgical
complications27–29. Traditional GDDs consists of a short
polymeric microscale tube that connects the anterior
chamber to a thin silicone plate for drainage of excess
AH30–32. While GDDs have been used to manage IOP for
glaucoma patients for the past 40 years, 15.1% of
implanted devices fail within 3 years and more than 29.8%
fail within 5 years post-implantation33,34. Clinical studies
have shown that up to 10% of glaucoma patients
require additional medications and surgical intervention
because of the tube blockage35. The hydrophobic polymer
materials from which GDDs are constructed (e.g., poly-
propylene, polymethylmethacrylate, and poly-
dimethylsiloxane) typically have high affinity for
interstitial proteins such as fibrinogen, immunoglobulin,
and albumin that adsorbs onto the device surface within
minutes after the implantation36–38. Once it forms, the
proteinaceous layer triggers the inflammatory response
that can lead to premature implantable device failure39.
Since GDDs generally have a drainage tube with an inner
diameter that ranges from 50 to 600 μm, the microscale
channel can easily be occluded by various biofouling
materials including vitreous, fibrin, or blood clot40–43.
One promising approach that can remove adsorbed
biofouling material is to ablate occlusion using
neodymium-doped yttrium aluminum garnet (Nd:YAG)
laser. However, there are several potential risks associated
with laser treatments including focal cataracts, prolonged
elevation of the intraocular pressure, posterior capsule
rupture, retinal injury, and laser injury44–50. Tissue plas-
minogen activator (tPA), which is a serine protease
involved in the breakdown of fibrin or blood clots, has
also been used to clear occluded glaucoma shunts51,52.
However, tPA may cause additional undesirable compli-
cations such as hyphema, active bleeding, and vitreous
hemorrhage53–55.
Establishing a method to non-invasively remove bio-
fouling without causing side effects can significantly
improve the reliability and functionality of many
chronically implanted devices. Here we report on the
design, fabrication, and testing of anti-biofouling micro-
tube integrated with an array of magnetic microactuators
as a part of a self-clearing GDD that can actively combat
against proteinaceous biofouling in situ without the need
for additional surgical or pharmaceutical interventions.
We believe our strategy to remove bioaccumulation on-
demand using externally applied magnetic field is a way
to significantly improve the functional lifetime of
implantable devices that suffer from biofouling-related
performance degradation. By integrating thin-film mag-
netic microactuators fabricated out of liquid crystal
polymer (LCP) using maskless lithography, here we
demonstrate a low-cost prototype of self-clearing GDD
drainage tube (Fig. 1). Using fluorescent-tagged bovine
serum albumin, we show the protein-clearing capabilities
of these prototype GDD microtubes using time-varying
magnetic fields, which may eliminate the need for addi-
tional surgical or pharmaceutical interventions for glau-
coma patients.
Results
Device fabrication and mechanical characterization
Figure 2a shows our microfabricated LCP-based device.
The needle-shape was chosen to accommodate the rela-
tively small tube diameter. We can control the deflection
direction and amplitude of the microactuator by adjusting
the strength and the direction of the externally applied
magnetic field (Fig. 2b). We assembled the microdevices
into a prototype GDD drainage tube using an anchor to
demonstrate protein-removal performance inside the
tube (Fig. 2c). Once manually placed into the microtube,
we heated the tube and applied tensile stress at both
ends to decrease the diameter of the microtube and fix
the microactuators in position, which prevented any
shifting of devices during actuation in a continuous
fluid flow.
To characterize the actuation capabilities of our mag-
netic microactuators, we evaluated the static and dynamic
mechanical responses. A magnetic moment of the soft
ferromagnetic element is generated when the magnetic
microactuator is placed in a static magnetic field. The
microactuators can deflect out of plane when the direc-
tion of the applied magnetic field is normal to the mag-
netization direction of the ferromagnetic element
(Fig. 2b). The deflection angle of magnetic microactuator
can be described in the ref. 56
ϕ ¼ Vm
~M ´ ~H
 
kbeam
ð1Þ
with the angular deflection ϕ, magnet volume Vm, mag-
netization ~M, applied magnetic field ~H , and the flexure
stiffness kbeam. The beam geometry and the material
property affect the mechanical stiffness of the flexure with
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following
kbeam ¼ Ecwt
3
12l
ð2Þ
with the elastic modulus Ec, beam width w, beam thick-
ness t, and beam length l57,58.
As shown in Fig. 3a, the measured deflection angle
corresponded closely with the theoretical values. We
varied the frequency and amplitude of the externally-
applied, time-varying magnetic fields using a custom
electromagnet to obtain the frequency response (10–200
Hz) of our microactuators (Fig. 3b). As expected, the
amplitude of deflection increased as a function of applied
magnetic field strength. Furthermore, we determined that
the actuation frequency of 20 Hz to be the primary
resonance, which can be used to generate the highest
dynamic deflection amplitude. The increase in dynamic
deflection amplitude may be attributable to the increase in
mean fluid velocity around the microactuator, which leads
to an increase in the wall shear stress on the micro-
actuator and the tube59,60. Therefore, we used a fixed
actuation frequency (20 Hz) with the highest actuation
amplitude (64°) for all experiments and simulation.
To verify these Ti-coated LCP based microactuator is
robust enough to withstand a large number of actuation
cycles in physiological condition, we examined the changes
in the dynamic responses of these microdevices in 37 °C
phosphate buffered saline (PBS, ThermoFisher Scientific,
Waltham, MA, USA). After 10.9 million actuation cycles,
we saw no visible damage to the LCP-based microactuators
and no change in the resonant frequency of tested devices
(n= 4, Supplementary Fig. 1). If we assume a 5-min weekly
actuation, this equates to up to 35 years of lifetime, which
suggests adequate robustness for our LCP-based micro-
actuators against fatigue related failure.
Fluid–structure interaction
We evaluated the shear stress distribution generated by
the microactuation motion using finite element modeling.
The simulation results showed that the maximum shear
stress is generated near the perimeter of the actuator
(Fig. 4a). When the device is integrated into the micro-
tube, the actuation leads to a larger shear stress as the
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Fig. 1 Microactuator based self-cleaning GDD. a 3D schematics of self-clearing GDD. b A custom maskless photolithography setup. c Fabrication
procedure for the magnetic microactuator
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microactuator approaches the tube wall (Fig. 4c). During
the actuation, the maximum shear stress of ~8 and ~10
dyn/cm2 are generated periodically on the surface of the
actuator and the tube, respectively (Fig. 4b, d).
BSA-FITC adsorption and desorption
To maximize the fluorescence intensity, we incubated
Ti-coated LCP samples in various concentrations of BSA-
FITC (1–8mg/ml) for 2 h. The fluorescence intensity of
absorbed BSA-FITC plateaued around 5mg/ml (Fig. 5a),
therefore, all subsequent BSA-FITC evaluations used this
concentration. The jet impingement technique is widely
used to analyze the shear stress required to remove cells
by corresponding the size of a lesion created by a per-
pendicular jet of fluid to a well-characterized shear stress
profile61,62. To quantify the adhesion strength of BSA-
FITC on Ti-coated LCP surface, we used the theoretical
description of the wall shear stress under the impinging
jet proposed by Phares et al.63. For this analysis, we
assumed that the AH is incompressible Newtonian fluid
in a steady and laminar flow. In the theoretical description
of the wall shear stress in normally impinging jet with jet
height H, the wall shear stress τ at a radial distance r can
be described by
τ
τm
¼ 0:18 1 e
114λ2
λ
 !
 0:943λe114λ2 ð3Þ
with the maximum shear stress τm and non-
dimensionalized jet height (λ= r/H). The maximum
shear stress τm is given by
τm ¼ 0:16 ρu
2
o
ðH=DÞ2 ð4Þ
with the fluid density ρ, the average flow velocity at the
nozzle exit uo, and diameter for the nozzle D. The critical
shear stress (τc) required to remove the adsorbed BSA-
FITC can then be calculated by measuring the radius of
lesion (Fig. 5b).
In the jet impingement test, the fluid jet was delivered at
a flow rate of 1.18 ml/min for 5 s, which corresponds to
Reynolds number of 100 in laminar flow range to be used
for Eqs. (3) and (4). The fluid jet created τm ~ 30 dyn/cm
2
which is in line with published shear stress value required
to rupture protein-ligand interaction64. Figure 5b shows
an image of BSA-FITC lesion created by jet impingement
and a plot of non-dimensional wall shear stress as a
function of non-dimensional lesion size for jet radius
Rjet= 125 μm. With an average lesion radius of 284 μm
(n= 4), the estimated shear stress required to remove
BSA-FITC (τc) was 10.2 dyn/cm
2. The numerical analysis
results (Fig. 4) showed that our magnetic microactuators
can generate up to 10 dyn/cm2. Taken together with the
results from our jet impingement study, we expected to
a
c
Magnetic field
Magnetic field
b
Fig. 2 Images of fabricated microactuators and self-clearing GDD. a Digital photograph of the fabricated magnetic microactuators. Scale bar=
200 μm b The deflected microactuator with different directional magnetic flux density with 13.7 mT. Scale bar= 200 μm. c Digital photographs of the
integrated microactuators in the lumen of a prototype GDD microtube. Scale bar= 500 μm
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show a robust protein removal using our prototype GDD
drainage tube.
Protein biofouling removal in GDD
The main function of our magnetic microactuators is to
remove the protein adsorbed on the device surface and
the inner wall of GDD microtube to prevent the initiation
of inflammatory cascade. As such, we quantified the
decrease in fluorescence intensity due to device actuation
on device surface and the inner wall of the microtube as
simulated in Fig. 4. To study anti-biofouling capability of
the actuator itself, we actuated BSA-FITC coated devices
with different actuation durations at 20 Hz. The max-
imum actuation duration was set to 5 min based on prior
literature65,66 and for practical consideration assuming
that a shorter actuation protocol would be less burden-
some on clinicians and patients. The minimum actuation
duration was set to be 30 s, which is 10% of the maximum
actuation duration.
Figure 6 demonstrates BSA-FITC removal due to
actuation of magnetic microdevices. We compared the
decreased fluorescence intensity values using one-way
analysis of variance (ANOVA) with Tukey’s HSD post-
hoc pairwise analysis. The results showed that BSA-FITC
coated on microactuators (n= 3) was significantly
reduced compared to non-actuated control regardless of
deflection amplitude or actuation duration (p < 0.01).
Without actuation, the fluorescence intensity decreased
by approximately 10–20% depending on treatment dura-
tion. However, the difference in fluorescent intensity
between the small (8°) and large (64°) deflection magni-
tudes was not statistically significant. The impact of
actuation duration was also statistically significant. When
actuated for 30 s, BSA-FITC amount reduced by 42%.
whereas up to 85% protein clearance can be seen on
device when actuated for 5 min. Thus, in subsequent
evaluations to determine the impact of actuation on
removing protein adsorbed on the microtube inner wall,
we actuated all samples for 5 min to maximize protein
clearance.
To demonstrate the in situ anti-biofouling performance
of our smart GDD, we coated the inner lumen of
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300-μm-diameter microtube integrated with our magnetic
microactuator using BSA-FITC (Fig. 2c). Figure 7a high-
lights the difference in fluorescence intensity between
actuated versus non-actuated GDD prototype. Without
actuation, we saw virtually no difference in fluorescence
intensity. Following actuation, however, we saw a sig-
nificant decrease in fluorescence intensity in areas sur-
rounding the microdevice. The pattern of cleared area
closely resembles the shear stress distribution predicted
by our numerical analysis (Fig. 4). We then quantified the
amount of fluorescence intensity decrease from the end of
the beams to the actuator tip and compared the results
using a two-sample t-test. The results show that the
microactuation can remove significant amount of adsor-
bed BSA from the tube wall compared to the non-
actuated control (p < 0.01, Fig. 7b). However, the decrease
in fluorescence intensity (<40%) in microtube was much
smaller than the 85% decrease we saw from the device
surface following a 5min actuation (Fig. 6b).
Discussion
Here we demonstrated that the LCP-based micro-
actuators can easily be fabricated at low-cost using our
maskless photolithography. LCP is widely used polymer in
biomedical applications due to their near hermetic
properties, biocompatibility and superior chemical resis-
tance67–70. By using commercially available low-cost LCP
sheets as the substrate in combination of highly scalable
microfabrication processes such as maskless photo-
lithography, oxygen etching, electroplating, and polymer
coating, it is possible to manufacture these LCP-based
devices at extremely low costs. Moreover, the simple
integration process that we employed to immobilize
microdevices inside a small drainage tube may be used to
create other smart MEMS-enabled catheter-based
devices.
Both the static and the dynamic responses of these
microfabricated LCP-based actuators corresponded well
with the theoretical values, which suggests a good control
of our fabrication process. The in vitro evaluation using
BSA-FITC showed that, as expected, the actuation from
our device can effectively reduce proteinaceous biofouling
on the actuator surface and the inner wall of the micro-
tube. The results from the in vitro experiments demon-
strated a good agreement with our results from the
numerical analysis that predicted the pattern of biofilm
clearance by quantifying the shear stress distribution and
the jet impingement study that quantified the adhesion
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strength of the BSA-FITC. This approach to quantify the
adhesion properties of specific biofilm and to model the
shear stress profile of a device actuation may be used in
future iterations to design novel microactuator arrays that
are tailored for bespoke implantable application against
specific biofouling materials.
To confirm that the biofouling removal process does
occur via mechanical shear generated by the micro-
actuation and not by the heat generated from the
microactuation, we also measured the amount of heat
generated during actuation (Supplementary Fig. 2). When
we actuated our microdevices (n= 4) for 5 min at 20 Hz
using 40mT in room temperature PBS, no temperature
increase was seen in thermal camera images (FLIR
A325sc, FLIR, Wilsonville, OR, USA). It is important to
ensure that no thermal effect occurs due to microactua-
tion since excessive heat may lead to unintended damage
to the surrounding tissue.
The potential implication of utilizing active mechanism
for combating biofouling is enormous since many
chronically implantable devices including biosensors,
neural interface electrodes, and drug delivery and drai-
nage devices suffer from significant performance
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degradation due to biofouling39,71. Although there is a
number of proposed mechanisms for actively addressing
biofouling using electrical and mechanical transducers65,
the magnetically-powered actuators have several key
advantages. First, the magnetic device can be activated
in situ wirelessly via externally applied magnetic field with
low power requirements (Supplementary Fig. 3) without
the need for any invasive procedure. Second, the magnetic
microactuators can be tailored to deliver large disruptive
forces to remove multi-scale biofouling materials includ-
ing protein, bacteria, and cells. Third, the lack of inte-
grated circuit and internal power source can facilitate the
integration and packaging of these type of devices into
existing medical devices, which can accelerate clinical
adoption. Finally, as mentioned, the simple design is
compatible with many scalable microfabrication technol-
ogies that can significantly reduce the cost of
manufacturing.
Despite these key benefits, there are several remaining
questions to be answered. First, the amount of protein
removed from the microtube wall was much lower than
that from the actuator surface despite our numerical
analysis demonstrating a higher maximum shear stress on
the wall. This may be due to the fact that each microscope
image was focused on microactuator surface, which is
located at the center of the microtube. As can be seen
from Fig. 4 and the Supplementary Video, the magnitude
of shear stress distribution around the mid-plane of
microtube is much lower than the top and bottom of the
microtube. It may be interesting to characterize protein
distribution using a confocal microscope in the future to
verify this hypothesis. If not, it is possible to leverage our
predictive modeling to redesign microactuators that can
provide a greater average shear stress to ensure a more
efficient protein-removal. Secondly, additional experi-
ments are needed to determine optimum actuation duty
cycle that will ensure a protein-free GDD microtube.
Although the microactuators were able to demonstrate
good protein reduction in just 5 min, it may be possible to
reduce this actuation duration further by performing a
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systematic evaluation. Thirdly, although it is possible to
integrate many microactuators into a long microtube
(Supplementary Fig. 4), the manual assembly process can
be further streamlined if 1D arrays of microactuators are
fabricated to better control the device spacing. Finally,
additional in vitro and in vivo work is necessary to
ascertain whether periodically removing biofilm using our
self-clearing implants will actually prolong the device
lifetime and improve patient outcome. A critical question
to address is to determine what happens with the dis-
placed biofouling material. A detailed histopathological
evaluations using animal models must be performed to
ensure that the displaced biomaterial will not cause
undesirable downstream effects.
Materials and methods
Device fabrication
We fabricated the microactuators from copper-(Cu)-
cladded LCP using a custom maskless photolithography
setup previously described72. We used a computer con-
nected to a conventional home theater projector with a
digital micromirror device (HD142X, Optoma, Fremont,
CA, USA) to project and expose a desired pattern72–75.
The projector was vertically fixed on a stereo-microscope
(SM-4B, Amscope, Irvine, CA, USA) using a custom
machined bracket. To improve the resolution and reduce
the size of the image, we optimized the alignment between
the lens of the microscope, the sample stage, and the
projector. We used Microsoft PowerPoint to design and
project various mask patterns. We adjusted the exposure
intensity by modifying pattern color in the software. Fig-
ure 1c shows the overall process flow for the device
fabrication.
The commercially available LCP sheet (Ultralam 3850,
Rogers corporation, Chandler, AZ, USA) has a thickness of
25 μm. To improve compliance of the cantilevers, we
reduced the LCP thickness to 8 μm using a reactive ion
etcher (RIE, PlasmaPro80, Oxford Instruments plc,
Abingdon, Oxfordshire, United Kingdom) after removing
Cu from one side using a wet Cu etchant (CE-100,
Transene, Danvers, MA, USA). We then mounted the
8-μm-thick single clad LCP sheet onto a carrier wafer
using a positive photoresist (PR) (AZ9260, Microchem,
Westborough, MA, USA) with the Cu on top. We spin
coated AZ9260 onto the Cu layer and exposed the canti-
levers designs using our custom maskless photo-
lithography setup. After etching the Cu layer using a wet
Cu etchant (CE-100, Transene, Danvers, MA, USA), we
removed PR using acetone. Next, we defined the Ni
magnet electroplating mold on spin-coated AZ9260 using
the same maskless photolithography procedure. We elec-
troplated Ni to achieve a final thickness of 20 μm. After
removing the PR, we etched the cantilever pattern on bare
LCP layer using an RIE and removed the remaining Cu
layer using a chemical etchant (BTP, Transene, Danvers,
MA, USA). Finally, we coated the device with 100 nm thick
titanium (Ti) using a sputterer (Magnetron sputtering
systems, PVD Products, Inc., Wilmington, MA, USA) on
both sides to improve biocompatibility.
Mechanical characterization
We measured the magnitudes of angular deflections for
a range of applied magnetic flux density up to 40.9 mT.
We used a bespoke iron-core electromagnet to generate
the magnetic field. We quantified the strength of magnetic
field using a commercial gaussmeter (Model 8010, Pacific
Scientific OECO, Milwaukie, OR, USA). We then placed
the device on top of the electromagnet and applied the
magnetic field of varying amplitude and frequency. We
imaged the deflected actuators using a digital microscope
KH8700, Hirox, Hackensack, NJ, USA) and calculated the
deflection angles from the images using imageJ software
(version 1.50i). To better characterize the motion of the
devices in liquid, we also characterized the dynamic
responses of the magnetic microactuators in deionized
water using a custom laser deflecting setup. Using a
mirror, we placed a laser beam onto the metallic surface
of the device, which then reflected the laser beam onto a
position sensitive diode (PSD) sensor. We recorded the
two-dimensional position data from the PSD using a
custom data acquisition system (LabView 2014, Austin,
TX, USA).
Fatigue evaluation
As a baseline, we photographed and measured the
dynamic responses of each test sample (n= 4). We
immobilized each microactuator on glass slide using
polyimide tape for the fatigue evaluation. We then placed
the glass slide fixture in a beaker filled with PBS at 37 °C.
We actuated the device for 6 days to achieve 10.9 million
cycles at 12 mT and 20 Hz sinusoidal signal. Following the
continuous actuation, the microactuators were removed
from the beaker, photographed, and analyzed for post-
actuation dynamic response.
Fluid–structure interaction
To determine the shear stress generated by the actua-
tion, we used a finite volume method to simulate shear
stress on the surface of microactuator and the lumen of
the microtube by numerically solving Navier–Stokes
equations. We discretized the computational domain
using a uniform, staggered, cartesian grid. We used Euler
explicit method for time discretization and spatial deri-
vatives in convective and computed diffusive terms using
the quadratic upstream interpolation for convective
kinematics and central difference schemes, respectively76.
Furthermore, we coupled the pressure and velocity using
a projection method77. We implemented a distributed
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Lagrange multiplier method to simulate the motion of
microactuator in a viscous fluid, which allowed us to
accurately capture the hydrodynamic interaction between
the microactuator and a surrounding fluid and evaluate
the shear stress acting on the surface78,79.
Protein-based biofouling adhesion
We tested the anti-biofouling performance of our
magnetic microactuators using fluorescent-tagged bovine
serum proteins (BSA-FITC, ThermoFisher Scientific,
Waltham, MA, USA), which is readily coated onto the
implant surface via non-specific binding and subsequently
initiates the inflammatory response in vivo80. We incu-
bated the devices and samples for jet impingement test in
the BSA-FITC solution of various concentrations
(1–8mg/ml) in PBS (n= 5, each) for 2 h and rinsed with
deionized water. We captured the images of protein
coated samples using a fluorescence microscope (Axio
Observer Z1, Carl Zeiss Microscopy, LLC) and a filter set
17 (excitation, BP 485/20, and emission BP 515-565, Carl
Zeiss Microscopy, LLC), and quantified the fluorescence
intensity using imageJ. We normalized each image using
the imageJ against bare non-coated sample.
We quantified the magnitude of shear stress required to
remove the absorbed protein on Ti-coated surface using a
jet impingement experiment. We vertically placed the tip
of a 15-ml syringe with the needle having an inner dia-
meter of 250 μm (7018333, Nordson EFD, East Provi-
dence, RI, USA) 1mm over BSA-FITC coated substrate
and delivered the jet flow using a syringe pump (NE-300,
New Era Pump Systems, Inc., Farmingdale, NY, USA). We
created a total of four lesions. Using the same fluores-
cence microscope describe above, we imaged of each
lesion and measured the diameter of each using imageJ.
We subtracted the background fluorescence from bare
substrate to normalize fluorescence intensity,
Protein biofouling removal in GDD
We investigated the impact of deflection amplitude (8° vs.
64°) and actuation duration (30 s vs. 5 min) of our magnetic
microactuators by quantifying the amount of BSA-FITC (n
= 3, each). We placed each sample in deionized water in a
custom testing chamber to block the ambient light during
actuation. We captured the fluorescence images of protein-
coated devices before and after the actuation and quanti-
fied the difference in fluorescence intensity using imageJ.
We normalized the background fluorescence by subtract-
ing fluorescencefrom a bare actuator surface. To demon-
strate the anti-biofouling capability of magnetic
microactuators inside a polytetrafluoroethylene microtube,
we coated the lumen of assembled GDD drainage tube by
flowing BSA-FITC at 2.7 μl/min, which is the average flow
rate of AH in human eyes. We then actuated the micro-
devices at 20 Hz for 5min to remove the adsorbed protein
layer (n= 3). Finally, we quantified the decrease in fluor-
escence level due to actuation and compared with the non-
actuated controls.
Acknowledgements
This work was supported in part with The Jackson Laboratory - Purdue
University Collaborative Seed Grant, NIH NINDS (R21NS095287), and NIH/NCRR
Indiana CTSI (UL1TR001108).
Authors’ contributions
H.P., S.J., and H.L. conceived the experiments, H.P. fabricated the samples and
conducted experiments, A.R. and A. A. performed the numerical analysis, and
all authors analyzed the results and reviewed the manuscript.
Author details
1Weldon School of Biomedical Engineering, Birck Nanotechnology Center,
Center for Implantable Devices, Purdue University, West Lafayette, IN 47907,
USA. 2School of Mechanical Engineering, Purdue University, West Lafayette, IN
47907, USA. 3Howard Hughes Medical Institute, The Jackson Laboratory, Bar
Harbor, ME 04609, USA
Conflict of interest
The authors declare that they have no conflict of interest.
Supplementary Information accompanies this paper at https://doi.org/
10.1038/s41378-018-0032-3.
Received: 7 June 2018 Revised: 16 August 2018 Accepted: 18 August 2018.
Published online: 5 November 2018
References
1. Lee, D. A. & Higginbotham, E. J. Glaucoma and its treatment. Am. J. Health Syst.
Pharm. 62, 691–699 (2005).
2. Mariotti, S. P. Global data on visual impairments 2020. Technical Report (World
Health Organization, 2010).
3. Quigley, H. A. & Broman, A. T. The number of people with glaucoma
worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262–267 (2006).
4. Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma
burden through 2040: a systematic review and meta-analysis. Ophthalmology
121, 2081–2090 (2014).
5. Broman, A. T. et al. Estimating the rate of progressive visual field damage in
those with open-angle glaucoma, from cross-sectional data. Invest. Ophthal-
mol. Vis. Sci. 49, 66–76 (2008).
6. Ko, F. et al. Diabetes, triglyceride levels, and other risk factors for glaucoma in
the National Health and Nutrition Examination Survey 2005–2008. Invest.
Opthalmol. Vis. Sci. 57, 2152 (2016).
7. Drance, S., Anderson, D. R. & Schulzer, M., Collaborative Normal-Tension
Glaucoma Study Group. Risk factors for progression of visual field abnorm-
alities in normal-tension glaucoma. Am. J. Ophthalmol. 131, 699–708 (2001).
8. Muñoz, B. et al. Causes of blindness and visual impairment in a population of
older Americans: The Salisbury Eye Evaluation Study. Arch. Ophthalmol. 118,
819–825 (2000).
9. Gupta, P. et al. Prevalence of Glaucoma in the United States: The 2005–2008
National Health and Nutrition Examination Survey. Invest. Ophthalmol. Vis. Sci.
57, 2905–2913 (2016).
10. Rein, D. B. et al. The economic burden of major adult visual disorders in the
United States. Arch. Ophthalmol. 124, 1754 (2006).
11. Seiler, T. & Wollensak, J. The resistance of the trabecular meshwork to aqueous
humor outflow. Clin. Exp. Ophthalmol. 229, 265–270 (1982).
12. Gabelt, B. T. & Kaufman, P. L. Changes in aqueous humor dynamics with age
and glaucoma. Prog. Retin. Eye Res. 24, 612–637 (2005).
13. Mark, H. H. Aqueous humor dynamics in historical perspective. Surv. Oph-
thalmol. 55, 89–100 (2010).
14. Kenneth Schwartz, D. B. Current management of glaucoma. Curr. Opin.
Ophthalmol. 8, 339–342 (2003).
15. Bito, L. Z. Prostaglandins: a new approach to glaucoma management with a
new, intriguing side effect. Surv. Ophthalmol. 41 Suppl 2, S1–S14 (1997).
Park et al. Microsystems & Nanoengineering            (2018) 4:35 Page 10 of 12
16. Zimmerman, T. J. W. P. B. I. The beta-adrenergic blocking agents and the
treatment of glaucoma. Surv. Ophthalmol. 23, 347–362 (1979).
17. Thom, J. & Herbert, E. Timolol A beta-adrenergic blocking agent for the
treatment of glaucoma. Arch. Ophthalmol. 95, 601–604 (1977).
18. Coakes, R. L. & Brubaker, R. F. The mechanism of timolol in lowering intraocular
pressure. Arch. Ophthalmol. 96, 2045 (1978).
19. Strahlman, E., Tipping, R., Vogel, R. & Group, tI. D. S. A double-masked, ran-
domized 1-Year study comparing dorzolamide (Trusopt), timolol, and betax-
olol. J. Chem. Inf. Model. 53, 1689–1699 (2013).
20. Bloch, S., Rosenthal, A. R., Friedman, L. & Caldarolla, P. Patient compliance in
glaucoma. Br. J. Ophthalmol. 61, 531–534 (1977).
21. Bansal, R. K. & Tsai, J. C. Compliance/adherence to glaucoma medications—a
challenge. J. Curr. Glaucoma Pract. 1, 22–25 (2007).
22. Jones, E., Clarke, J. & Khaw, P. T. Recent advances in trabeculectomy technique
recent advances in trabeculectomy technique. Curr. Opin. Ophthalmol. 16,
107–113 (2005).
23. Mchugh, D., Marshall, J., Timothy, J., Hamilton, P. A. M. & Raven, A. Diode laser
trabeculoplasty (DLT) for primary open-angle glaucoma and ocular hyper-
tension. Br. J. Ophthalmol. 74, 743–747 (1990).
24. Juzych, M. S. et al. Comparison of long-term outcomes of selective laser
trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma.
Ophthalmology 111, 1853–1859 (2004).
25. Spurny, R. C. & Lederer, C. M. Krypton laser trabeculoplasty a clinical. Arch.
Ophthalmol. 102, 1626–1628 (1984).
26. Melamed, S., Pei, J. & Epstein, D. L. Delayed response to argon laser trabe-
culoplasty in monkeys morphological and morphometric analysis. Arch.
Ophthalmol. 104, 1078–1083 (1986).
27. Gedde, S. J. et al. Treatment outcomes in the tube versus trabeculectomy (TVT)
study after five years of follow-up. Am. J. Ophthalmol. 153, 789–803 (2012).
28. Ceballos, E. M., Parrish, R. K. & Schiffman, J. C. Outcome of Baerveldt glaucoma
drainage implants for the treatment of uveitic glaucoma. Ophthalmology 109,
2256–2260 (2002).
29. Ayyala, R. S., Duarte, J. L. & Sahiner, N. Glaucoma drainage devices: state of the
art. Expert. Rev. Med. Devices 3, 509–521 (2006).
30. Melamed, S. & Fiore, P. M. Molten implant surgery in refractory glaucoma. Surv.
Ophthalmol. 34, 441–448 (1990).
31. Rittenbach, T. L. Proptosis from a baerveldt tube shunt implant. Optom. Vis. Sci.
91, e145–8 (2014).
32. Sarkisian, S. R. Tube shunt complications and their prevention. Curr. Opin.
Ophthalmol. 20, 126–130 (2009).
33. Souza, C. et al. Long-term outcomes of Ahmed glaucoma valve implantation
in refractory glaucomas. Am. J. Ophthalmol. 144, 893–900 (2007).
34. Gedde, S. J. et al. Surgical complications in the tube versus trabeculectomy
study during the first year of follow-up. Am. J. Ophthalmol. 143, 804–814
(2007).
35. Schlote, T., Ziemssen, F. & Bartz-Schmidt, K. U. Pars plana-modified Ahmed
glaucoma valve for treatment of refractory glaucoma: a pilot study. Graefe’s
Arch. Clin. Exp. Ophthalmol. 244, 336–341 (2006).
36. Hill, R. A., Pirouzian, A. & Liaw, L. H. Pathophysiology of and prophylaxis against
late Ahmed glaucoma valve occlusion. Am. J. Ophthalmol. 129, 608–612
(2000).
37. Choritz, L. et al. Surface topographies of glaucoma drainage devices and their
influence on human tenon fibroblast adhesion. Invest. Ophthalmol. Vis. Sci. 51,
4047–4053 (2010).
38. Ihlenfeld, J. V. et al. Transient in vivo thrombus deposition onto polymeric
biomaterials: role of plasma fibronectin. Trans. Am. Soc. Artif. Intern. Organs
XXIV, 727–735 (1978).
39. Kenneth Ward, W. A review of the foreign-body response to subcutaneously-
implanted devices: the role of macrophages and cytokines in biofouling and
fibrosis. J. Diabetes Sci. Technol. 2, 768–777 (2008).
40. Coleman, A. L. et al. Initial clinical experience with the Ahmed glaucoma valve
implant in pediatric patients. Arch. Ophthalmol. 115, 186 (1997).
41. Dubey, S., Pegu, J., Agarwal, M. & Agrawal, A. Vitreous occlusion of tube
implant in a phakic patient with traumatic glaucoma. Oman J. Ophthalmol. 7,
2014–2016 (2014).
42. McClintock, M. & MacCumber, M. W. Lowered intraocular pressure in a
glaucoma patient after intravitreal injection of ocriplasmin. Clin. Ophthalmol. 9,
1995–1998 (2015).
43. Christakis, P. G. et al. The ahmed versus baerveldt study: three-year treatment
outcomes. Ophthalmology 120, 2232–2240 (2013).
44. Tsai, W. F., Chen, Y. C. & Su, C. Y. Treatment of vitreous floaters with neody-
mium YAG Laser. Br. J. Ophthalmol. 77, 485–488 (1993).
45. Kanner, E. M., Netland, P. A., Sarkisian, S. R. & Du, H. Ex-PRESS miniature
glaucoma device implanted under a scleral flap alone or combined with
phacoemulsification cataract surgery. J. Glaucoma 18, 488–491 (2009).
46. Tanito, M., Sano, I. & Ohira, A. A case report of progressive obstruction of Ex-
PRESS miniature glaucoma shunt after transient flat anterior chamber and
treatment using Nd:YAG laser. BMC Ophthalmol. 15, 4–6 (2015).
47. Song, J. Complications of selective laser trabeculoplasty: a review. Clin. Oph-
thalmol. 10, 137–143 (2016).
48. Perez, C. I., Chansangpetch, S., Hsia, Y. C. & Lin, S. C. Use of Nd:YAG laser to
recanalize occluded Cypass Micro-Stent in the early post-operative period. Am.
J. Ophthalmol. Case Rep. 10, 114–116 (2018).
49. Koo, E. H., Haddock, L. J., Bhardwaj, N. & Fortun, J. A. Cataracts induced by
neodymium-yttrium-aluminium-garnet laser lysis of vitreous floaters. Br. J.
Ophthalmol. 101, 709–711 (2017).
50. Hahn, P., Schneider, E. W., Tabandeh, H., Wong, R. W. & Emerson, G. G.
Reported complications following laser vitreolysis. JAMA Ophthalmol. 135,
973–976 (2017).
51. Smith, M. F. & Doyle, J. W. Use of tissue plasminogen activator to revive blebs
following intraocular surgery. Arch. Ophthalmol. 119, 809–812 (2001).
52. Raczyńska, D., Lipowski, P., Zorena, K., Skorek, A. & Glasner, P. Enzymatic
vitreolysis with recombinant tissue plasminogen activator for vitreomacular
traction. Drug Des. Dev. Ther. 9, 6259–6268 (2015).
53. Zalta, A. H., Sweeney, C. P., Zalta, A. K. & Kaufman, A. H. Intracameral tissue
plasminogen activator use in a large series of eyes with valved glaucoma
drainage implants. Arch. Ophthalmol. 120, 1487 (2002).
54. Sidoti, P. A. et al. Tissue plasminogen activator and glaucoma drainage. J.
Glaucoma 4, 258–262 (1995).
55. Lundy, D. C., Sidoti, P., Winarko, T., Minckler, D. & Heuer, D. K. Intracameral tissue
plasminogen activator after glaucoma surgery: indications, effectiveness, and
complications. Ophthalmology 103, 274–282 (1996).
56. Judy, J. W. & Muller, R. S. Magnetic microactuation of torsional polysilicon
structures. In The 8th International Conference on Solid-State Sensors and
Actuators, vol. 1770, 332–335 (1995).
57. Young, W. & Budynas, R. Roarks’s Formulas for Stress and Strain. 7th edn,
(McGraw-Hill, New York, 2002).
58. Judy, J. W., Muller, R. S., Fellow, L. & Actuation, A. S. Magnetically actuated,
addressable microstructures. J. Micro. Syst. 6, 249–256 (1997).
59. Große, W., S. Schröder. Mean wall-shear stress measurements using the micro-
pillar shear-stress sensor MPS3. Meas. Sci. Technol. 19, 015403 (2008).
60. Khaled, A. R. A., Vafai, K., Yang, M., Zhang, X., & Ozkan, C. S. Analysis, control and
augmentation of microcantilever deflections in bio-sensing systems. Sensors
Actuators, B Chem. 94, 103–115 (2003).
61. Visser, C. W. et al. Quantifying cell adhesion through impingement of a
controlled microjet. Biophys. J. 108, 23–31 (2015).
62. Bayoudh, S., Ponsonnet, L., Ouada, H. B., Bakhrouf, A. & Othmane, A. Bacterial
detachment from hydrophilic and hydrophobic surfaces using a microjet
impingement. Colloids Surf. A: Physicochem. Eng. Asp. 266, 160–167 (2005).
63. Phares, D. J., Smedley, G. T. & Flagan, R. C. The wall shear stress produced by
the normal impingement of a jet on a flat surface. J. Fluid. Mech. 418, 351–375
(2000).
64. Weisel, J. W., Shuman, H. & Litvinov, R. I. Protein – protein unbinding induced
by force: single-molecule studies. Curr. Opin. Struct. Biol. 13, 227–235 (2003).
65. Yeh, P. Y., Jayachandran, J. K., N. Madden, J. D. & Chiao, M. Electric field and
vibration-assisted nanomolecule desorption and anti-biofouling for biosensor
applications. Colloids Surf. B.59, 67–73 (2007).
66. Meyer, G. D., Moran-Mirabal, J. M., Branch, D. W. & Craighead, H. G. Nonspecific
binding removal from protein microarrays using thickness shear mode reso-
nators. IEEE. Sens. J. 6, 254–261(2006).
67. Wang, X., Engel, J. & Liu, C. Liquid crystal polymer for MEMS: processes and
applications. J. Micromech. Microeng. 13, 628–633 (2003).
68. Wang, K., Liu, C.-c, Member, S. & Durand, D. M. Oxide sputtered on liquid
crystal polymer. IEEE Trans. Biomed. Eng. 56, 6–14 (2009).
69. Chow, E. Y., Chlebowski, A. L. & Irazoqui, P. P. A miniature-implantable RF-
wireless active glaucoma intraocular pressure monitor. IEEE Trans. Biomed.
Circuits Syst. 4, 340–349 (2010).
70. Min, K. S. et al. A liquid crystal polymer-based neuromodulation system: an
application on animal model of neuropathic pain. Neuromodulation 17,
160–169 (2014).
Park et al. Microsystems & Nanoengineering            (2018) 4:35 Page 11 of 12
71. Yu, L., Kim, B. & Meng, E. Chronically implanted pressure sensors: challenges
and state of the field. Sensors 14, 20620–20644 (2014).
72. Park, H., John, S. & Lee, H. Low-cost rapid prototyping of liquid crystal polymer
based magnetic microactuators for glaucoma drainage devices. Proc. Annu.
Int. Conf. IEEE Eng. Med. Biol. Soc. 2016, 4212–4215 (2016).
73. Dunham, J. S., Musgraves, J. D., Close, B. T. & Tanenbaum, D. M. A maskless
photolithographic prototyping system using a low-cost consumer projector
and a microscope. Am. J. Phys. 73, 980–990 (2005).
74. Horiuchi, T., Koyama, S. & Kobayashi, H. Microelectronic engineering simple
maskless lithography tool with a desk-top size using a liquid- crystal-display
projector. Microelectron. Eng. 141, 37–43 (2015).
75. Li, Y. et al. Rapid fabrication of microfluidic chips based on the simplest LED
lithography. J. Micromech. Microeng. 055020, 1–7 (2015).
76. Leonard, B. P. Based on quadratic upstream interpolation. Comput. Methods
Appl. Mech. Eng. 19, 59–98 (1979).
77. Alexandre, B. & Chorin, J. Numerical solution of the Navier-Stokes equations.
Math. Comput. 22, 745–762 (1968).
78. Ardekani, A. M., Dabiri, S. & Rangel, R. H. Collision of multi-particle and general
shape objects in a viscous fluid. J. Comput. Phys. 227, 10094–10107
(2008).
79. Zhang, Y. & Li, A. G. Reduced viscosity for flagella moving in a solution of long
polymer chains. Phys. Rev. Fluids 3, 023101 (2018).
80. Kim, Y. K., Chen, E. Y. & Liu, W. F. Biomolecular strategies to modulate the
macrophage response to implanted materials. J. Mater. Chem. B 4, 1600–1609
(2015).
Park et al. Microsystems & Nanoengineering            (2018) 4:35 Page 12 of 12
